Global research trends on Phyllanthus emblica: a bibliometric and visual analysis from 1993 to 2024

doi:10.5246/jcps.2026.02.013

Abstract

Abstract:

Phyllanthus emblica, renowned for its medicinal and edible properties, has attracted increasing scholarly attention since the 1990s. The present study sought to deliver a comprehensive bibliometric analysis and elucidate the emerging research hotspots on P. emblica over the period 1993–2024. A systematic search of the Web of Science Core Collection (WOSCC) was conducted using relevant keywords, and bibliometric mapping was performed using CiteSpace and VOSviewer. A total of 860 publications were identified, spanning 363 journals, authored by 3402 researchers from 1068 institutions across 59 countries. India accounted for the highest number of publications, whereas the Chinese Academy of Sciences emerged as the most prolific institution. Yingjun Zhang and Chongren Yang were recognized as the leading contributor, and the Journal of Ethnopharmacology ranked first in publication volume. Keyword co-occurrence analysis indicated that current research predominantly centered on antioxidants, bioactive extracts, kinetics, antibacterial activity, tannins, phenolic compounds, acids, compound characterization, and apoptosis. This study offered a thorough global perspective on P. emblica research over the past three decades and provided strategic insights to inform and inspire future investigations.

Key words: Phyllanthus emblica, Bibliometric analysis, CiteSpace, VOSviewer, Research trends

Supporting:

Xiuliang Qiu, Yinxiang Lan. Global research trends on Phyllanthus emblica: a bibliometric and visual analysis from 1993 to 2024[J]. Journal of Chinese Pharmaceutical Sciences, 2026, 35(2): 173-186.

Figures/Tables 16

Table 1. The top nine most productive countries.

Table 2. The top 10 productive organizations.

Table 3. The top 10 authors by number of publications.

Table 4. The top 10 citation journals.

Table 5. The top five co-citation journals.

Table 6. The top 22 keywords co-occurrence.

References 40

[1]	Yadav, S.S.; Singh, M.K.; Singh, P.K.; Kumar, V. Traditional knowledge to clinical trials: A review on therapeutic actions of Emblica officinalis. Biomed. Pharmacother. 2017, 93, 1292–1302.
[2]	Nashine, S.; Kanodia, R.; Nesburn, A.B.; Soman, G.; Kuppermann, B.D.; Kenney, M.C. Nutraceutical effects of Emblica officinalis in age-related macular degeneration. Aging. 2019, 11, 1177–1188.
[3]	Hazarika, T.K.; Ningombam, L.; Debbarma, P.; Momin, M.D.; Lalrinzuala, P.; Devi, L.S. Genetic diversity analysis of Phyllanthus acidus Skeels of north-east India: Insights from multivariate analysis. Sci. Rep. 2025, 15, 6647.
[4]	Wu, M.; Liu, M.; Wang, F.Y.; Cai, J.H.; Luo, Q.Y.; Li, S.S.; Zhu, J.X.; Tang, Z.Z.; Fang, Z.F.; Wang, C.X.; Chen, H. The inhibition mechanism of polyphenols from Phyllanthus emblica Linn. fruit on acetylcholinesterase: A interaction, kinetic, spectroscopic, and molecular simulation study. Food Res. Int. 2022, 158, 111497.
[5]	Wu, M.; Cai, J.H.; Fang, Z.F.; Li, S.S.; Huang, Z.Q.; Tang, Z.Z.; Luo, Q.Y.; Chen, H. The composition and anti-aging activities of polyphenol extract from Phyllanthus emblica L. fruit. Nutrients. 2022, 14, 857.
[6]	Duan, X.Y.; Lin, L.Z.; Zhao, M.M. Hydrolyzable tannins and pectin are glycolipid lowering ingredients in Phyllanthus emblica Linn.: Valid interaction with gut action targets. Food Chem. 2025, 463, 141313.
[7]	Prananda, A.T.; Dalimunthe, A.; Harahap, U.; Simanjuntak, Y.; Peronika, E.; Karosekali, N.E.; Hasibuan, P.A.Z.; Syahputra, R.A.; Situmorang, P.C.; Nurkolis, F. Phyllanthus emblica: A comprehensive review of its phytochemical composition and pharmacological properties. Front. Pharmacol. 2023, 14, 1288618.
[8]	Hu, Q.; Wang, S.K.; Cheng, R.Y.; Liu, Y.Q.; Chang, Z.H.; Huang, Y.; Chen, Y.X.; Luo, X.W.; Zhou, L.P.; Wang, B.J.; Gao, Y.; Chen, H.J.; Liu, R.P.; Zhang, L.Z. Tannins in Phyllanthus emblica L. improves cisplatin efficacy in lung cancer cells by boosting endoplasmic reticulum stress to trigger immunogenic cell death. Phytomedicine. 2024, 123, 155219.
[9]	Suvandee, W.; Teeranachaideekul, V.; Jeenduang, N.; Nooeaid, P.; Makarasen, A.; Chuenchom, L.; Techasakul, S.; Dechtrirat, D. One-pot and green preparation of Phyllanthus emblica extract/silver nanoparticles/polyvinylpyrrolidone spray-on dressing. Polymers. 2022, 14, 2205.
[10]	Wang, R.B.; Xu, X.Y.; Puja, A.M.; Perumalsamy, H.; Balusamy, S.R.; Kim, H.; Kim, Y.J. Gold nanoparticles prepared with Phyllanthus emblica fruit extract and bifidobacterium animalis subsp. lactis can induce apoptosis via mitochondrial impairment with inhibition of autophagy in the human gastric carcinoma cell line AGS. Nanomaterials. 2021, 11, 1260.
[11]	Liu, X.L.; Cui, C.; Zhao, M.M.; Wang, J.S.; Luo, W.; Yang, B.; Jiang, Y.M. Identification of phenolics in the fruit of emblica (Phyllanthus emblica L.) and their antioxidant activities. Food Chem. 2008, 109, 909–915.
[12]	Lin, H.Y.; Lin, C.H.; Kuo, Y.H.; Shih, C.C. Antidiabetic and antihyperlipidemic activities and molecular mechanisms of Phyllanthus emblica L. extract in mice on a high-fat diet. Curr. Issues Mol. Biol. 2024, 46, 10492–10529.
[13]	Sharif, M.A.; Khan, A.M.; Salekeen, R.; Rahman, M.H.; Mahmud, S.; Bibi, S.; Biswas, P.; Hasan, M.N.; Islam, K.M.D.; Mahbubur Rahman, S.M.; Islam, M.E.; Alshammari, A.; Alharbi, M.; Hayee, A. Phyllanthus emblica (Amla) methanolic extract regulates multiple checkpoints in 15-lipoxygenase mediated inflammopathies: Computational simulation and in vitro evidence. Saudi Pharm. J. 2023, 31, 101681.
[14]	Varnasseri, M.; Siahpoosh, A.; Hoseinynejad, K.; Amini, F.; Karamian, M.; Yad, M.J.Y.; Cheraghian, B.; Khosravi, A.D. The effects of add-on therapy of Phyllanthus emblica (Amla) on laboratory confirmed COVID-19 Cases: A randomized, double-blind, controlled trial. Complementary Ther. Med. 2022, 65, 102808.
[15]	Chen, J.D.; Chen, S.Y.; Liao, C.C.; Fang, C.Y.; Yen, G.C. Enhancing cognitive memory function using Phyllanthus emblica polysaccharides via modulating autophagy and reshaping the gut microbiota. Food Funct. 2025, 16, 8140–8159.
[16]	Li, G.F.; Yu, Q.; Li, M.Q.; Zhang, D.K.; Yu, J.; Yu, X.H.; Xia, C.X.; Lin, J.Z.; Han, L.; Huang, H.Z. Phyllanthus emblica fruits: a polyphenol-rich fruit with potential benefits for oral management. Food Funct. 2023, 14, 7738–7759.
[17]	Saifulazmi, N.F.; Rohani, E.R.; Harun, S.; Bunawan, H.; Hamezah, H.S.; Nor Muhammad, N.A.; Azizan, K.A.; Ahmed, Q.U.; Fakurazi, S.; Mediani, A.; Sarian, M.N. A review with updated perspectives on the antiviral potentials of traditional medicinal plants and their prospects in antiviral therapy. Life. 2022, 12, 1287.
[18]	Huang, S.Q.; Li, S.L.; Li, G.Y.; Wang, C.Y.; Guo, X.H.; Zhang, J.; Liu, J.; Xu, Y.; Wang, Y.C. Fabrication and characterization of Phyllanthus emblica extract-polyvinyl alcohol/carboxymethyl cellulose sodium antioxidant hydrogel and its application in wound healing. Pharmaceutics. 2024, 16, 1531.
[19]	Avinash, P.G.; Hamid, Shams, R.; Dash, K.K.; Shaikh, A.M.; Ungai, D.; Harsányi, E.; Suthar, T.; Kovács, B. Recent insights into the morphological, nutritional and phytochemical properties of Indian gooseberry (Phyllanthus emblica) for the development of functional foods. Plants. 2024, 13, 574.
[20]	Zhang, Y.; Lu, L.S.; Zheng, R. Emerging trends and focus on immune checkpoint inhibitors for non-small cell lung cancer treatment: visualization and bibliometric analysis. Front. Pharmacol. 2023, 14, 1140771.
[21]	Zhang, M.; Kou, L.; Qin, Y.Y.; Chen, J.W.; Bai, D.Z.; Zhao, L.; Lin, H.Y.; Jiang, G.H. A bibliometric analysis of the recent advances in diazepam from 2012 to 2021. Front. Pharmacol. 2022, 13, 1042594.
[22]	Wang, Y.; Lu, X.J.; Yue, X.F.; Kan, L.W.; Du, S.Z. Bibliometric analysis of PCSK9 inhibitors for cardiovascular diseasemanagement based on Web of Science. J. Chin. Pharm. Sci. 2025, 34, 232–250.
[23]	Li, B.X.; Wu, T.; Dong, M.F.; Ye, K.; Wang, J.; Ren, C.D. Immunotherapy research for prostate cancer from 2000 to 2024: A bibliometric and visualization analysis. Transl. Androl. Urol. 2025, 14, 3064–3087.
[24]	Wang, Y.; Rao, Y.F.; Lin, Z.J.; Sa, R.N.; Yin, Y.L.; Zhang, X.M.; Zhang, B. Current status and trends of research on anthracycline-induced cardiotoxicity from 2002 to 2021: A twenty-year bibliometric and visualization analysis. Oxid. Med. Cell. Longev. 2022, 2022, 6260243.
[25]	Lan, Y.X.; Qiu, X.L.; Huang, D.D. Bibliometric and visual analysis of global research on snake venom disintegrins (2009–2023). J. Chin. Pharm.Sci. 2024, 33, 1012–1024.
[26]	Sabe, M.; Chen, C.M.; Perez, N.; Solmi, M.; Mucci, A.; Galderisi, S.; Strauss, G.P.; Kaiser, S. Thirty years of research on negative symptoms of schizophrenia: A scientometric analysis of hotspots, bursts, and research trends. Neurosci. Biobehav. Rev. 2023, 144, 104979.
[27]	Ling, L.X.; Ouyang, Y.B.; Hu, Y. Research trends on nanomaterials in gastric cancer: A bibliometric analysis from 2004 to 2023. J. Nanobiotechnol. 2023, 21, 248.
[28]	Zhao, J.; Liao, B.; Gong, L.; Yang, H.Y.; Li, S.; Li, Y.S. Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis. Hum. Vaccines Immunother. 2023, 19, 2254262.
[29]	Yu, Z.Y.; Xie, L.; Zhang, J.; Lin, H.; Niu, T. The evolution of minimal residual disease: Key insights based on a bibliometric visualization analysis from 2002 to 2022. Front. Oncol. 2023, 13, 1186198.
[30]	Ran, Y.H.; Fan, Y.Y.; Yang, G.; Li, P.Y.; Zhang, Y.J.; Xu, T.F.; Zheng, X.; Wei, T. Frontiers and hotspots evolution in robot-assisted thyroidectomy: A bibliometric analysis from 2008 to 2023. Gland Surg. 2025, 14, 1923–1936.
[31]	Zhang, Y.; Liu, X.Y.; Qiao, X.F.; Fan, Y.B. Characteristics and emerging trends in research on rehabilitation robots from 2001 to 2020: Bibliometric study. J. Med. Internet Res. 2023, 25, e42901.
[32]	Guo, Y.; Zhang, H.Q.; Yu, X.Q. A bibliometric analysis of complement in IgA nephropathy from 1991 to 2022. Front. Pharmacol. 2023, 14, 1200193.
[33]	Yang, X.L.; Yin, H.; Zhang, D.Y.; Peng, L.S.; Li, K.L.; Cui, F.; Xia, C.C.; Li, Z.S.; Huang, H.J. Bibliometric analysis of cathepsin B research from 2011 to 2021. Front. Med. 2022, 9, 898455.
[34]	Gulati, R.; Agarwal, S.; Agrawal, S. Hepatoprotective studies on Phyllanthus emblica Linn. and quercetin. Indian J. Expl. Biol. 1995, 33, 261–268.
[35]	Murugesan, S.; Kottekad, S.; Crasta, I.; Sreevathsan, S.; Usharani, D.; Perumal, M.K.; Mudliar, S.N. Targeting COVID-19 (SARS-CoV-2) main protease through active phytocompounds of ayurvedic medicinal plants–Emblica officinalis (Amla), Phyllanthus niruri Linn. (Bhumi Amla) and Tinospora cordifolia (Giloy)–A molecular docking and simulation study. Comput. Biol. Med. 2021, 136, 104683.
[36]	Begum, M.A.; Hossain, R.; Jain, D.; Murti, Y.; Agrawal, K.K.; Janmeda, P.; Neto, I.C.P.; Coutinho, H.D.M.; Raposo, A.; Saraiva, A.; Han, H.; Romão, B.; Lisboa, P.; Moreira, P.; Islam, M.T. Recent insights into the antimicrobial properties of Phyllanthus emblica L.: A comprehensive review of wonder berry. Chem. Biodivers. 2024, 21, e202400747.
[37]	Hegde, S.N.; Lavanya Devi, K.; Choudhary, M.; Menon, N.; Singh, G. A comprehensive metabolome profiling of Terminalia chebula, Terminalia bellerica, and Phyllanthus emblica to explore the medicinal potential of Triphala. Sci. Rep. 2024, 14, 31635.
[38]	Zhang, L.M.; Yuan, J.M.; Pu, T.L.; Qu, W.L.; Lei, X.; Ma, K.H.; Qian, K.J.; Zhao, Q.L.; Liao, C.F.; Jin, J. Chromosome-scale genome assembly of Phyllanthus emblica L. ‘Yingyu’. DNA Res. 2025, 32, dsaf006.
[39]	Tiwana, G.; Cock, I.E.; Cheesman, M.J. Phyllanthus emblica: phytochemistry, antimicrobial potential with antibiotic enhancement, and toxicity insights. Microorganisms. 2025, 13, 611.
[40]	Saini, R.; Kumar, V.; Patel, C.N.; Sourirajan, A.; Dev, K. Synergistic antibacterial activity of Phyllanthus emblica fruits and its phytocompounds with ampicillin: A computational and experimental study. Naunyn Schmiedeberg’s Arch. Pharmacol. 2024, 397, 857–871.